Literature DB >> 2615928

Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients.

R J Mathew1, W H Wilson.   

Abstract

Changes in regional cerebral blood flow and behavioral and physiological indices were monitored after intravenous administration of d-amphetamine sulfate and placebo in groups of patients with schizophrenia and normal volunteers. Amphetamine administration was associated with decreased anxiety, emotional withdrawal, depressed mood, blunted affect and increased excitement in the patients. Subjects who received amphetamine showed significant increases in systolic and diastolic blood pressure and reduction in end-tidal carbon dioxide. Post-amphetamine cerebral blood flow was decreased equally in both patients and controls. The blood flow change, however, did not show any regional variations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2615928     DOI: 10.1159/000118564

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  4 in total

1.  Amphetamine and negative symptoms of schizophrenia.

Authors:  M Sanfilipo; A Wolkin; B Angrist; D P van Kammen; E Duncan; S Wieland; T B Cooper; E D Peselow; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

2.  Methamphetamine causes sustained depression in cerebral blood flow.

Authors:  Oksana Polesskaya; Jharon Silva; Christine Sanfilippo; Taylor Desrosiers; Anita Sun; Jie Shen; Changyong Feng; Aleksey Polesskiy; Rashid Deane; Berislav Zlokovic; Karl Kasischke; Stephen Dewhurst
Journal:  Brain Res       Date:  2010-12-13       Impact factor: 3.252

3.  Amphetamine challenge decreases yohimbine binding to α2 adrenoceptors in Landrace pig brain.

Authors:  Anne M Landau; Doris J Doudet; Steen Jakobsen
Journal:  Psychopharmacology (Berl)       Date:  2012-01-07       Impact factor: 4.530

4.  PET measurement of dopamine D2 receptor-mediated changes in striatopallidal function.

Authors:  K J Black; M H Gado; J S Perlmutter
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.